# Journey Clinical

> Journey Clinical is a New York-based healthtech company that operates a collaborative-care platform enabling licensed psychotherapists to offer Ketamine-Assisted Psychotherapy (KAP) inside their own private practices. Its in-house medical team handles patient eligibility, ketamine prescriptions, and ongoing medical monitoring, while therapists deliver the preparation, dosing, and integration sessions. The model expands safe, legal access to psychedelic-assisted care for patients with depression, anxiety, PTSD, and other conditions, and has grown to a network of over 2,500 trained providers.

- **Founded:** 2020
- **Headquarters:** New York, New York, United States
- **Founders:** Jonathan Sabbagh (Co-Founder & Executive Chairman (former CEO)), Myriam Barthes (Co-Founder & CEO)
- **Team size:** ~100 employees
- **Products:** Ketamine-Assisted Psychotherapy (KAP), Collaborative Care Platform for Therapists, Medical Team & Medication Management, Spravato (esketamine) Treatment, KAP Education & Provider Training
- **Notable:** Built a network of 2,500+ KAP-trained licensed therapists across 21+ states, Raised ~$12M total, including an $8.5M Series A led by Union Square Ventures (USV's first psychedelics investment), Pioneered a collaborative-care model that separates the medical (prescribing) role from the psychotherapy role

## Products & services

- **Ketamine-Assisted Psychotherapy (KAP)** — A collaborative-care program combining legal, sublingual ketamine lozenges with structured preparation, dosing, and integration psychotherapy sessions delivered by a licensed therapist in the Journey Clinical network.
- **Collaborative Care Platform for Therapists** — A membership platform giving independent psychotherapists the tools, KAP training, in-house medical team, and clinical infrastructure to offer ketamine-assisted therapy within their own practice.
- **Medical Team & Medication Management** — In-house prescribers and medical staff who handle patient eligibility screening, ketamine prescription, dosing protocols, and ongoing outcome monitoring.
- **Spravato (esketamine) Treatment** — Support for FDA-approved esketamine nasal spray treatment within the collaborative-care framework.
- **KAP Education & Provider Training** — Comprehensive education modules and peer consultation groups certifying therapists to deliver ketamine-assisted psychotherapy.

## Achievements

- Built a network of 2,500+ KAP-trained licensed therapists across 21+ states
- Raised ~$12M total, including an $8.5M Series A led by Union Square Ventures (USV's first psychedelics investment)
- Pioneered a collaborative-care model that separates the medical (prescribing) role from the psychotherapy role
- Established in-network insurance coverage with multiple major national payers
- Assembled an in-house medical and scientific advisory team spanning psychiatry, nursing, and psychedelic research

## Latest updates

- **2024-08** — Latest reported funding activity / continued expansion of the therapist network and services.
- **2023-01** — Closed $8.5M Series A led by Union Square Ventures, bringing total funding to roughly $12M.
- **2021-09** — Raised $3M seed round led by Fifty Years to scale the therapist platform.

## Links

- Website: https://www.journeyclinical.com
- LinkedIn: https://www.linkedin.com/company/journey-clinical
- Twitter/X: https://twitter.com/journeyclinical
- Instagram: https://www.instagram.com/journeyclinical
- Facebook: https://www.facebook.com/journeyclinical

---

Profile page: https://yespress.io/journey-clinical
Published by YesPress — https://yespress.io
Last updated: 2026-07-20